Searching for metachronous tumours in patients with head and neck cancer: The ideal protocol!

Current Opinion in Otolaryngology and Head and Neck Surgery

Volumn 18, Issue 2, 2010, Pages 124-133

  Bradley, Patrick J ^a   Bradley, Paula T ^b  

^a QUEEN S MEDICAL CENTRE   (United Kingdom)

^b ROYAL ALBERT EDWARD INFIRMARY   (United Kingdom)

Author keywords

Endoscopy; Head and neck cancer; Imaging; Metachronous tumours; Screening protocol; Second tumours

Indexed keywords

RADIOPHARMACEUTICAL AGENT;

CANCER DIAGNOSIS; CANCER PATIENT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; ENDOSCOPY; FLUORESCENCE SPECTROSCOPY; HEAD AND NECK CANCER; HIGH RISK PATIENT; HUMAN; ISOTOPE LABELING; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTPATIENT; PRIORITY JOURNAL; REVIEW; THORAX RADIOGRAPHY;

CLINICAL PROTOCOLS; EARLY DIAGNOSIS; ENDOSCOPY; FOLLOW-UP STUDIES; HEAD AND NECK NEOPLASMS; HUMANS; MAGNETIC RESONANCE IMAGING; MOUTH; NEOPLASMS, SECOND PRIMARY; TUMOR MARKERS, BIOLOGICAL; VIDEOTAPE RECORDING;

EID: 77949627480     PISSN: 10689508     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOO.0b013e3283374ccf     Document Type: Review

References (112)

1. Billroth T, Von WIniwarter AA. A general surgical pathology and therapeutics. New York, USA: Appleton; 1883.
2. Warren S, Gates O. Multiple primary malignant tumour: a survey of the literature and a statistical study. Am J Cancer 1932; 16:1358-1414.
3. Slaughter DP, Southwick HW, Smejkal W. Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer 1953; 6:963-968.
4. Schantz SP, Spitz MR, Hsu TC. Mutagen sensitivity in patients with head and neck cancers; a biological marker for risk of multiple primary malignancies. J Natl Cancer Inst 1990; 82:1773-1775.
5. Jefferies S, Eeles R, Goldgar D, et al. The role of genetic factors in predisposition to squamous cell carcinoma of the head and neck. Br J Cancer 1999; 79:865-867.
6. Sturgis EM, Wei Q. Genetic susceptibility-molecular epidemiology of head and neck cancer. Curr Opin Oncol 2002; 14:310-317.
7. Argiris A, Brockstein BE, Haraf DJ, et al. Competing causes of death and second primary tumours in patients with locoregionally advanced head and neck cancer treated with chemoradiotherapy. Clin Cancer Res 2004; 10:1956-1962.
8. Syrjanen KJ, Pyrhonen S, Syrijanen SM. Evidence suggesting human papillomavirus (HPV) aetiology for squamous cell papilloma of the paranasal sinus. Arch Geschwulstforsch 1983; 53:77-82.
9. Gillison ML, D'Souza G, Westra W, et al. Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst 2008; 100:407-420.
10. Licitra L, Zigon G, Gatta G, et al. Human papillomavirus in HNSCC: a European epidemiologic perspective. Hematol Oncol Clin North Am 2008; 22:1143-1153.
11. Fakhry C, Westra WH, Li S, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 2008; 100:261-269.
12. Gillison ML, Harris J, Westra W, et al. Survival outcomes by tumour human papillomavirus (HPV) status in stage III-IV oropharyngeal cancer (OPC) in RTOG 0129 [abstract #6003]. J Clin Oncol 2009; 27 (15 Suppl).
13. Farshadpour F, Hordijk GJ, Koole R, Slootweg PJ. Nonsmoking and nondrinking patients with head and neck squamous cell carcinoma: a distinct population. Oral Dis 2007; 13:239-243.
14. Dahistrom KR, Little JA, Zafereo ME, et al. Squamous cell carcinoma of the head and neck in never smoker-never drinkers: a descriptive epidemiologic study. Head Neck 2008; 30:75-84.
15. Svhwartz LH, Ozsahin M, Zhang GN, et al. Synchronous and metachronous head and neck carcinomas. Cancer 1994; 74:1933-1998.
16. Yu KK, Zanation AM, Moss JR, Yarabrough WG. Familial head and neck cancer: molecular analysis of a new clinical entity. Laryngoscope 2002; 112:1587-1593.
17. Jefferies S, Goldgar D, Eeles R, et al. The accuracy of cancer diagnosis as reported in families with head and neck cancer: a case-control study. Clin Oncol (R Coll Radiol) 2008; 20:309-314.
18. Panosetti E, Luboinski B, Mamelle G, Richard JM. Multiple, synchronous and metachronous cancers of the upper aerodigestive tract: a nine-year study. Laryngoscope 1989; 99:1267-1273.
19. Cianfraglia F, Di Gregorio DA, Manieri A. Multiple primary tumours in patients with oral squamous cell carcinoma. Oral Oncol 1999; 35:157-163.
20. Leon X, Ferlito A, Myer CM, et al. Second primary tumours in head and neck cancer patients. Acta Orolaryngol 2002; 122:765-778.
21. Rennemo E, Zatterstrome U, Boysen M. Impact of second primary tumour on survival in head and neck cancer: an analysis of 2,063 cases. Laryngoscope 2008; 118:1350-1356.
22. Scantz SP, Anderson PE, Weymuller EA, et al., editors. Cancer patients follow-ups. St Louis, Missouri, USA: C.V. Mosby; 1997. pp. 57-77.
23. Dhooge IJ, de Vos M, van Cauwenberge PB. Multiple primary malignant tumours in patients with head and neck cancer: results of a prospective study and future perspectives. Laryngoscope 1998; 108:250-256.
24. Sturgis EM, Miller RH. Second primary malignancies in the head and neck cancer patient. Ann Otol Rhinol Laryngol 1995; 104:946-954.
25. Lin K, Patel SG, Chu PY, et al. Second primary malignancy of the aerodigestive tract in patients treated for cancer of the oral cavity and larynx. Head Neck 2005; 27:1042-1048.
26. Hsu Y-B, Chang S-Y, Lan M-C, et al. Second primary malignancies in squamous cell carcinomas of the tongue and larynx: an analysis of incidence, pattern and outcome. J Chin Med Assoc 2008; 71:86-91.
27. Chuang SC, Scelo G, Tonita JM, et al. Risk of secondary primary cancer among patients with head and neck cancers: a pooled analysis of 13 cancer registries. Int J Cancer 2008; 123:2390-2396.
28. Jones AS, Morar P, Phillips DE, et al. Second primary tumours in patients with head and neck squamous cell carcinoma. Cancer 1995; 75:1343-1353.
29. Leon X, Quer M, Diaz S, et al. Second neoplasm in patients with head and neck cancer. Head Neck 1999; 21:204-210.
30. Lee P, de Bree R, Brokx HAP, et al. Primary lung cancer after treatment of head and neck cancer without lymph node metastasis: is there a role for autofluorescence bronchoscopy? Lung Cancer 2008; 62:309-315.
31. Leon X, del Prado VM, Orus C, et al. Influence of the persistence of tobacco and alcohol use in the appearance of second neoplasm in patients with a head and neck cancer. A case-control study. Cancer Causes Control 2009; 20:645-652.
32. Wolpoe ME, Goldenberg D, Koch WM. Squamous cell carcinoma of the sinonasal cavity arising as a second primary in individuals with head and neck cancer. Laryngoscope 2006; 116:696-699.
33. Tsou Y-A, Hua C-H, Tseng H-C, et al. Survival and treatment strategy for second primary malignancies in patients with head and neck squamous cell carcinoma and nasopharyngeal carcinoma. Acta Otolaryngol 2007; 127:651-657.
34. Scelo G, Boffetta P, Corbex M, et al. Second primary cancers in patients with nasopharyngeal carcinoma; a pooled analysis of 13 cancer registries. Cancer Causes Control 2007; 18:269-278.
35. Merkx MA, van Gullick JJ, Marres HA, et al. effectiveness of routine follow-up of patients treated for T1-2N0 oral squamous cell carcinoma of the floor of mouth and tongue. Head Neck 2006; 28:1-7.
36. Holland JM, Arsanjan A, Liem BJ, et al. Second malignancy in early stage laryngeal carcinoma patients treated with radiotherapy. J LaryngolOtol 2002; 116:190-193.
37. Sjogren EV, Snijder S, van Beekum J, et al. Second malignant neoplasia in early (T1S-T1) glottis carcinoma. Head Neck 2006; 28:501-507.
38. Di Martino E, Sellhaus B, Haussmann R, et al. Survival in second primary malignancies of patients with head and neck cancer. J Laryngol Otol 2002; 116:831-838.
39. van der Haring IS, Schaapveld MS, Roodenburg JLN, De Bock GH. Second primary tumours after a squamous cell carcinoma of the oral cavity oropharynx using a cumulative incidence method. Int J Oral Maxillofac Surg 2009; 38:332-338.
40. Rice DH, Spiro RH. Current concepts in head and neck cancer. Atlanta, Georgia, USA: American Cancer Society; 1989.
41. Cooney TR, Poulsen MG. Is routine follow-up useful after combined-modality therapy for advanced head and neck cancer? Arch Otolaryngol Head Neck Surg 1999; 125:379-382.
42. Johnson FE, Virgo KS, Clemente MF, et al. How tumour stage affects surgeons' surveillance strategies after surgery for carcinoma of the upper digestive tract. Cancer 1998; 82:1932-1937.
43. Manikantan K, Khode S, Dwivedi RC, et al. Making sense of posttreatment surveillance in head and neck cancer: the when and what of follow-up. Cancer Treat Rev 2009; 35:744-753.
44. Johnson FE, Johnson MH, Virgo MH. Current follow strategies after potentially curative resection of upper aerodigestive tract epidermoid carcinoma: results of a survey of members of The Society of Head and Neck Surgeons. Int J Oncol 1997; 10:927-931.
45. De Visscher AVM, Manni JJ. Routine long-term follow-up in patients treated with curative intent for squamous cell carcinoma of the larynx, pharynx, and oral cavity. Arch Otolaryngol Head Neck Surg 1994; 120:934-939.
46. Virgo KS, Panielo RC, Johnson FE. Costs of posttreatment surveillance for patients with upper aerodigestive tract cancer. Arch Otolaryngol Head Neck Surg 1998; 124:564-572.
47. Schwartz DL, Barker J Jr, Chansky K, et al. Postradiotherapy surveillance practice for head and neck squamous cell carcinoma: too much for too little? Head Neck 2003; 25:990-999.
48. Vaamonde P, Martin C, Del Rio M, LaBella T. Second primary malignancies in patients with cancer of the head and neck. Otolaryngol Head Neck Surg 2003; 129:65-70.
49. Bhattacharyya N. An assessment of risk factors for the development of a second primary malignancy in the head and neck. Ear Nose Throat J 2006; 85:121-125.
50. Haas I, Hauser U, Ganzer U. The dilemma of follow-up in head and neck cancer patients. Eur Arch Otorhinolaryngol 2001; 258:177-183.
51. Leon X, Del Prado Venegas M, Orus C, et al. Metachronous second primary tumours in the aerodigestive tract in patients with early stage head and neck squamous cell carcinoma. Eur Arch Otorhinolaryngol 2005; 262:905-909.
52. Boysen M, Lovdal O, Tausjo J, Winther F. The value of follow-up in patients treated for squamous cell carcinoma of the head and neck. Eur J Cancer 1992; 28:426-430.
53. Snow GB. Follow-up in patients treated for head and neck cancer: how frequent, how through and for how long. Eur J Cancer 1992; 28:315-316.
54. Morton RP, David Hay K, Macann A. On completion of curative treatment of head and neck cancer: why follow up? Curr Opin Otolaryngol Head Neck Surg 2004; 12:142-146.
55. Van Agthoven M, Van Ineveld BM, De Boer M, et al. The costs of head and neck oncology: primary tumours, recurrent tumours and long-term follow-up. Eur J Cancer 2001; 37:2204-2211.
56. Agrawal A, De Silva BW, Buckley BM, Schuller DE. Role of physician versus the patient in the detection of recurrent disease following treatment of head and neck cancer. Laryngoscope 2004; 114:232-235.
57. Smit M, Balm AJ, Hilgers FJ, Tan IB. Pain as a sign of recurrent disease in head and neck squamous cell carcinoma. Head Neck Surg 2001; 23:372-375.
58. Scharpf JS, Karnell LH, Christensen AJ, Funk GF. The role of pain in head and neck cancer recurrence and survivorship. Ach Otolaryngol Head Neck Surg 2009; 135:789-794.
59. De Veld DCG, Witjes MJH, Sternborg HJCM, Roodenburg JLN. The status of in vivo autofluorescence spectroscopy and imaging ion oral oncology. Oral Oncol 2005; 41:117-131.
60. Driemel O, Kunkel M, Hullmann M, et al. Diagnosis or oral squamous cell carcinoma and its precursor lesions. J Dtsch Dermatol Ges 2007; 5:1095-1100.
61. Lingen MW, Kalmar JR, Karrison T, Speigh PM. Critical evaluation of diagnostic aids for the detection of oral cancer. Oral Oncol 2008; 44:10-22.
62. Jayanthi JL, Mallia RJ, Shiny SJ, et al. Discriminant analysis of autofluorescence spectra for classification of oral lesions in vivo. Laser Surg Med 2009; 41:345-352.
63. Neel HB. Routine endoscopy: is it necessary every time? Arch Otolaryngol 1984; 110:531-532.
64. Davidson J, Gilbert R, Irish J, et al. The role of panedoscopy in the management of mucosal head and neck malignancy: a prospective evaluation. Head Neck 2000; 22:449-455.
65. Atabek U, Mohit-Tabatabai MA, Raina S, et al. Lung cancer in patients with head and neck cancer; incidence and long-term survival. Am J Surg 1987; 154:434-438.
66. Haughey BH, Gates GA, Arfken CL, Harvey J. Meta-analysis of second malignant tumours in head and neck cancer; the case for an endoscopic screening protocol. Arch Otolaryngol Head Neck Surg 1992; 101 (2 Pt 1): 105-112.
67. Benninger MS, Shariff A, Blazoff K. Symptom-directed selective endoscopy: long-term efficacy. Arch Otolaryngol Head Neck Surg 2001; 127:770-773.
68. Guardiola E, Chaigneau L, Villanueva C, Pivot X. Is there still a role for triple endoscopy as part of staging for head and neck cancers? Curr Opin Otolaryngol Head Neck Surg 2006; 14:85-88.
69. Wang CP, Lee YC, Lou PJ, et al. Unsedated transnasal oesophogoduodenoscopy for the evaluation of dysphagia following treatment for previous primary head and neck cancer. Oral Oncol 2009; 45:615-620.
70. Postma GN. Transnasal oesophogoscopy. Curr Opin Otolaryngol Head Neck Surg 2006; 14:156-158.
71. D'Ippolito R, Foresi A, Castagnetti C, et al. Indications for flexible fiberoptic bronchoscopy and its safety in the very elderly. Monaidi Arch Chest Dis 2007; 67:23-29.
72. Petit T, Georges C, Jung G-M, et al. Systematic oesophageal endoscopic screening in patients previously treated for head and neck squamous cell carcinoma. Ann Oncol 2001; 12:643-646.
73. Lo OS-H, Law S, Wei WI, et al. Esophageal cancers with synchronous or antecedent head and neck cancers: a more formidable challenge? Ann Surg Oncol 2008; 15:1750-1756.
74. Watanabe A, Hosokawa M, Taniguuchi M, et al. Head and neck cancer associated with oesophageal cancer. Auris Nasus Larynx 2007; 37:207-211.
75. Lee Y-C, Wang C-P, Chen C-C, et al. Transnasal endoscopy with narrow band imaging and Lugol staining to screen patients with head and neck cancer whose condition limits oral intubation with standard endoscopy (with video). Gastrointest Endosc 2009; 69:408-417.
76. Moschler O, Spahn TW, Middelberg-Bisping C, et al. Chromoendoscopy is a valuable tool for screening of high-risk patients with head and neck cancer for early detection of oesophageal cancer. Digestion 2006; 73:160-166.
77. Katada C, Makayama M, Tanabe S, et al. Narrow band imaging for detecting metachronous superficial oropharyngeal and hypopharyngeal squamous cell carcinomas after chemoradiotherapy for head and neck cancers. Laryngoscope 2008; 118:1787-1790.
78. Scherubl H, Steinberg J, Schwertner C, et al. Coincidental squamous cell cancers of the oesophagus, head and neck: risk and screening [in German]. HNO 2008; 56:603-608.
79. Upile T, Jerjes W, Sterenborg HJCM, et al. Head and neck optical diagnostics: vision of the future surgery. Head Neck Oncol 2009; 1:25.
80. Gillenwater A, Jacob R, Richard-Kortum R. Fluorescence spectroscopy: a technique with potential to improve the early detection of aerodigestive neoplasia. Head Neck 1998; 20:556-562.
81. Roblyer D, Kurachi C, Stepanek V, et al. Objective detection and delineation of oral neoplasia using autofluorescence imaging. Cancer Prev Res 2009; 2:423-431.
82. Piazza C, Cocco D, De Bebedetto L, et al. Narrow band imaging and high definition television in the assessment of laryngeal cancer: a prospective study on 279 patients. Eur Arch Otorhinolaryngol 2009. [Epub ahead of print]
83. Arens C, Reussner D, Woenkhaus J, et al. Indirect fluorescence laryngoscopy in the diagnosis of precancerous and cancerous laryngeal lesions. Eur Arch Otorhinolaryngol 2007; 264:621-626.
84. Moghissi K, Dixon K, Stringer MR. Current indications and future perspective of fluorescence bronchoscopy; a review study. Photodiagnosis Photodyn Ther 2008; 5:238-246.
85. Lippman SM, Hong WK. Second malignant tumours in head and neck squamous cell carcinoma; the over shadowing threat for patients with early-stage disease. Int J Radiat Oncol Biol Phys 1989; 17:691-694.
86. Ferlito A, Shaha AR, Silver CE, et al. Incidence and sites of distant metastases from head and neck cancer. ORL J Otorhinolaryngol Relat Spec 2001; 63:202-207.
87. Mercer RR, Lucas NC, Simmons AN, et al. Molecular discrimination of multiple primary versus metastatic squamous cell carcinoma of the head/ neck and lung. Exp Mol Pathol 2009; 86:1-9.
88. Geurs TW, Balm AJ, van Velthuysen ML, et al. Survival after surgical resection of pulmonary metastases and second primary squamous cell lung carcinomas in head and neck cancer. Head Neck 2009; 31:220-226.
89. Geurts TW, Ackerstaff AH, Van Zandwijk N, et al. The psychological impact of annual chest X-ray follow-up in head and neck cancer. Acta Otolaryngol 2006; 126:1315-1320.
90. Humphris GM, Rogers S, McNally D, et al. Fear of recurrence and possible cases of anxiety and depression in orofacial cancer patients. Int J Oral Maxillofac Surg 2003; 32:486-491.
91. Llewellyn CD, Weinmann J, McGurk M, Humphris G. Can we predict which head and neck cancer survivors develop fears of recurrence? J Psychosom Res 2008; 65:525-532.
92. Rogers SN, El-Sheikha J, Lowe D. The development of a patients concerns inventory (PCI) to help reveal patients concerns in the head and neck clinic. Oral Oncol 2009; 45:555-561.
93. Shah SI, Applebaum EL. Lung cancer after head and neck cancer: the role of chest radiography. Laryngoscope 2000; 110:2033-2036.
94. Warner GC, CoxGJ. Evaluation of chest radiography versus chest computed tomography in screening for pulmonary malignancy in advanced head and neck cancer. J Otolaryngol 2003; 32:107-109.
95. Ong TK, Kerewala CJ, Martin IC, Stafford FW. The role of thorax imaging in staging head and neck squamous cell carcinoma. J Craniomaxillofac Surg 1999; 27:339-344.
96. Hsu YB,Chu PY, Liu JC, et al. Role of chest computed tomography in head and neck cancer. Arch Otolaryngol Head Neck Surg 2008; 134:1050-1054.
97. Isles MG, McConkey C, Mehenna HM. A systematic review and metaanalysis of the role of positron emission tomography in the follow-up of head and neck squamous cell carcinoma following radiotherapy or chemoradiotherapy. Clin Otolaryngol 2008; 33:210-222.
98. Kim SY, Roh J-L, Yeo N-K, et al. Combined 18F-fluorodeoxyglucose-positron emission tomography and computed tomography as a primary screening method for detecting second primary cancers and distant metastases in head and neck cancer. Ann Oncol 2007; 18:1698-1703.
99. Bold B, Piao Y, Murata Y, et al. Usefulness of PET/CT for detecting a second primary cancer after treatment for squamous cell carcinoma of the head and neck. Clin Nucl Med 2008; 33:831-833.
100. Khan N, Oriuchi N, Nimiya H, et al. Positron emission tomographic imaging with 11C-choline in differential diagnosis of head and neck tumours: comparison with 18F-FDG PET. Ann Nucl Med 2004; 18:409-412.
101. Borjesson PK, Jauw YW, Boellaard R, et al. Performance of immune-positron emission tomography with zirconium-89-labeled chimeric monoclonal antibody U36 in the detection of lymph node metastases in head and neck cancer patients. Clin Cancer Res 2006; 12 (7pt1):2133-2140.
102. Pantaleo MA, Nannini M, Maleddu A, et al. Experimental results and related clinical implications of PET detection of epidermal growth factor receptor (EGFr) in cancer. Ann Oncol 2009; 20:213-226.
103. Schoder H, Fury M, Lee N, Kraus D. PET monitoring of therapy response in head and neck squamous cell carcinoma. J Nucl Med 2009; 50 (Suppl 1): 74S-88S.
104. Miller FR, Karnad AB, Eng T, et al. Management of the unknown primary carcinoma: long-term follow-up on a negative PET scan and negative panendoscopy. Head Neck 2008; 30:28-34.
105. Som PM, Genden EM. Surveillance of the patient [chapter 11]. In: Head and neck cancer; an evidence-based team approach. Genden EM, Varvares MA, editors. New York, USA: Thieme; 2008.
106. Shin DM, Lee JS, Lippman SM, et al. P53 expressions: predicting recurrence and second primary tumours in head and neck squamous cell carcinoma. J Natl Cancer Inst 1996; 88:519-529.
107. Wu X, Zhao H, Do KA, et al. Serum levels of insulin growth factor (IGF-1 and IGF-binding protein predict risk of second primary tumours in patients with head and neck cancer. Clin Cancer Res 2004; 10 (12 pt 1):3988-3995.
108. Wu X, Gu J, Dong Q, Huang M, et al. Joint effect of mutagen sensitivity and insulin-like growth factors in predicting the risk of developing secondary primary tumors and tumor recurrence in patients with head and neck cancer. Clin Cancer Res 2006; 12:7194-7201.
109. Liu X, Chen Z, Yu J, Zhou X. MicroRNA profiling and head and neck cancer. Comp Funct Genomics 2009. [Epub ahead of print]
110. Harris AT, Lungari A, Needham CJ, et al. Potential for Raman spectroscopy to provide cancer screening using peripheral blood sample. Head Neck Oncol 2009; 1:34.
111. Wu X, Spitz MR, Lee JJ, et al. Novel susceptibility loci for second primary tumours/recurrence in head and neck cancer patients: large-scale evaluation of genetic variants. Cancer Prev Res 2009; 2:617-624.
112. Wilson JMG, Jungner G. Principles and practice of screening for disease. Public Health Paper no 34. Geneva, Switzerland: WHO; 1968